Document is current
Any future updates will be listed below
-
Authors
Shi, Hongcheng
Guo, Jianming
Fan, Wei
Li, Yonghong
Huang, Rui
Dong, Qiang
Yang, Zhi
Yang, Yong
Wang, Xinlu
Gu, Di
Huo, Li
Ji, Zhigang
Wang, Feng
Xu, Danfeng
Jiang, Zhiqiang
Li, Haifu
Li, Jialu
Li, Runqin
Qi, Luyuan
Wang, Jing https://orcid.org/0000-0002-2781-7753
Ye, Dingwei
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals (Novartis Pharmaceuticals)
- License Information
-
More Information
Article History
Received: 19 June 2025
Accepted: 16 February 2026
First Online: 1 March 2026
Declarations
:
: This study was completed in compliance with the Declaration of Helsinki and Good Clinical Practice Guidelines. The trial protocol was approved by the Medical Ethics Committees of Fudan University Zhongshan Hospital, Beijing Cancer Hospital, and the First Affiliated Hospital of Guangzhou Medical University, and the Ethics Committees of Sun Yat-sen University Cancer Center and Clinical Trial, West China Hospital of Sichuan University. Informed consent was obtained from all participants, and all participant data were deidentified for publication.
: Not applicable.
: HS, JG, WF, YL, RH, QD, ZY, YY, XW, DG, LH, ZJi, FW, DX, JW, and DY have no disclosures to report. ZJiang, HL, JL, RL, and LQ are employees of Novartis Pharmaceuticals and holders of Novartis stock.
